Redeye acknowledges a milestone for Nanexa with the successful GMP (“Good Manufacturing Practice”) authorization of its Uppsala manufacturing unit. Nanexa is now allowed to produce clinical material for trials, including the company’s upcoming NEX-18 phase 1 trial. Next step is permission to start the trial. We see these two catalysts as essential steps toward Nanexa’s most important trigger, the readout of the phase I trial.